NCT00703820 · OUTCOME

Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Alone.

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia · Source last updated 2021-08-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of participants
Interval / dispersion: 95% Confidence Interval
Time frame: 3 years after completion of therapy

What was measured

Kaplan-Meier estimate of the probability of being alive and free of relapse or second malignancy three years after protocol enrollment

Analysis population: Randomized standard risk patients who received chemotherapy only

Groups in this outcome

Cytarabine+Daunorubicin+Etoposide

Patients received Cytarabine + Daunorubicin + Etoposide as their first course of chemotherapy. Subsequent therapy is risk-adapted.

Clofarabine+Cytarabine

Patients received Clofarabine + Cytarabine as their first course of chemotherapy. Subsequent therapy is risk- adapted.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Cytarabine+Daunorubicin+Etoposide	51
Clofarabine+Cytarabine	41

Reported measurements

Source class 1

Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Cytarabine+Daunorubicin+Etoposide	55.6	Not reported	43.3	71.4	Not reported
Clofarabine+Cytarabine	54.3	Not reported	40.6	72.5	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
43.3
upper Limit
71.4
value
55.6
group Id
OG001
lower Limit
40.6
upper Limit
72.5
value
54.3

denoms

counts
group Id
OG000
value
51
group Id
OG001
value
41
units
Participants

description

Kaplan-Meier estimate of the probability of being alive and free of relapse or second malignancy three years after protocol enrollment

dispersion Type

95% Confidence Interval

groups

description
Patients received Cytarabine + Daunorubicin + Etoposide as their first course of chemotherapy. Subsequent therapy is risk-adapted.
id
OG000
title
Cytarabine+Daunorubicin+Etoposide
description
Patients received Clofarabine + Cytarabine as their first course of chemotherapy. Subsequent therapy is risk- adapted.
id
OG001
title
Clofarabine+Cytarabine

param Type

NUMBER

population Description

Randomized standard risk patients who received chemotherapy only

reporting Status

POSTED

time Frame

3 years after completion of therapy

title

Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Alone.

type

SECONDARY

unit Of Measure

Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice